Spots Global Cancer Trial Database for Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Official Title: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Study ID: NCT04586478
Conditions
Interventions
Study Description
Brief Summary: The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.
Detailed Description: The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL. The study consists of screening period (8 weeks), treatment period (4 weeks), and follow-up period (2 years at most).
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Boren Hospital, Beijing, Beijing, China
Beijing Cancer Hospital, Beijing, Beijing, China
Peking University Third Hospital, Beijing, Beijing, China
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Xinqiao Hospital of TMMU, Chongqing, Chongqing, China
Guangdong Provincial Peoples' Hospital, Guangzhou, Guangdong, China
SunYat-Sen University Cancer Center, Guangzhou, Guangdong, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Tongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Tongji Hospital of Tongji University, Shanghai, Shanghai, China
West China Hospital，Sichuan University, Chengdu, Sichuan, China
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
The First Affiliated Hospital, Zhejiang University school of Medicine, Hangzhou, Zhejiang, China
Contact Details
Name: Dehui Zou, Dr.
Affiliation: Institute of Hematology & Blood Diseases Hospital, China
Role: PRINCIPAL_INVESTIGATOR
Name: Weili Zhao, Dr.
Affiliation: Ruijin Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
